Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 2
2015 2
2016 6
2017 3
2018 4
2019 7
2020 24
2021 40
2022 29
2023 36
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Banwell B, et al. Lancet Neurol. 2023 Mar;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24. Lancet Neurol. 2023. PMID: 36706773 Review.
Autoimmune Encephalitis Misdiagnosis in Adults.
Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, Zitser J, Gelfand JM, Day GS, Dunham SR, Rodenbeck SJ, Clardy SL, Solomon AJ, Pittock SJ, McKeon A, Dubey D, Zekeridou A, Toledano M, Turner LE, Vernino S, Irani SR. Flanagan EP, et al. JAMA Neurol. 2023 Jan 1;80(1):30-39. doi: 10.1001/jamaneurol.2022.4251. JAMA Neurol. 2023. PMID: 36441519 Free PMC article.
Adverse Events in NMOSD Therapy.
Giglhuber K, Berthele A. Giglhuber K, et al. Int J Mol Sci. 2022 Apr 9;23(8):4154. doi: 10.3390/ijms23084154. Int J Mol Sci. 2022. PMID: 35456972 Free PMC article. Review.
In this review, we summarise current knowledge on the adverse effects of azathioprine, mycophenolate mofetil, rituximab, tocilizumab, eculizumab, satralizumab, and inebilizumab in NMOSD. Infections, cytopenias, and infusion-related reactions are most common, but the data a …
In this review, we summarise current knowledge on the adverse effects of azathioprine, mycophenolate mofetil, rituximab, tocilizumab, eculiz …
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E, Correale J. Carnero Contentti E, et al. J Neuroinflammation. 2021 Sep 16;18(1):208. doi: 10.1186/s12974-021-02249-1. J Neuroinflammation. 2021. PMID: 34530847 Free PMC article. Review.
Phase III studies have shown significant relapse reduction compared to placebo in AQP4-ab-positive patients treated with satralizumab, an interleukin-6 receptor (IL-6R) inhibitor, inebilizumab, an antibody against CD19(+) B cells; and eculizumab, an antibody blocking the C …
Phase III studies have shown significant relapse reduction compared to placebo in AQP4-ab-positive patients treated with satralizumab, an in …
Neuromyelitis Optica Spectrum Disorders.
Costello F. Costello F. Continuum (Minneap Minn). 2022 Aug 1;28(4):1131-1170. doi: 10.1212/CON.0000000000001168. Continuum (Minneap Minn). 2022. PMID: 35938660 Review.
Accordingly, four recent randomized controlled trials have demonstrated the efficacy of three new NMOSD therapies, namely eculizumab, satralizumab, and inebilizumab. SUMMARY: Currently, NMOSD poses both diagnostic and treatment challenges. ...
Accordingly, four recent randomized controlled trials have demonstrated the efficacy of three new NMOSD therapies, namely eculizumab, satral …
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA. Solomon AJ, et al. Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5. Lancet Neurol. 2023. PMID: 37479377 Review.
Update on neuromyelitis optica spectrum disorder.
Holroyd KB, Manzano GS, Levy M. Holroyd KB, et al. Curr Opin Ophthalmol. 2020 Nov;31(6):462-468. doi: 10.1097/ICU.0000000000000703. Curr Opin Ophthalmol. 2020. PMID: 33009077 Free PMC article. Review.
The three drugs that were tested for prevention of NMOSD relapses were eculizumab, inebilizumab, and satralizumab. All of the trials were worldwide, placebo-controlled, double-masked studies that demonstrated a clear benefit with each approach. ...
The three drugs that were tested for prevention of NMOSD relapses were eculizumab, inebilizumab, and satralizumab. All of the trials …
New therapies for neuromyelitis optica spectrum disorder.
Levy M, Fujihara K, Palace J. Levy M, et al. Lancet Neurol. 2021 Jan;20(1):60-67. doi: 10.1016/S1474-4422(20)30392-6. Epub 2020 Nov 10. Lancet Neurol. 2021. PMID: 33186537 Review.
RECENT DEVELOPMENTS: Four randomised controlled trials have tested the efficacy of three new therapies (eculizumab, satralizumab, and inebilizumab) for patients with neuromyelitis optica spectrum disorder that all showed a benefit in preventing future attacks. ...
RECENT DEVELOPMENTS: Four randomised controlled trials have tested the efficacy of three new therapies (eculizumab, satralizumab, and ine …
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Epub 2023 Sep 7. J Neurol. 2024. PMID: 37676297 Free PMC article. Review.
Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive t …
Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - m …
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. Paul F, et al. Neurol Neuroimmunol Neuroinflamm. 2023 May 31;10(4):e200124. doi: 10.1212/NXI.0000000000200124. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37258412 Free PMC article.
Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD (eculizumab, inebilizumab, and satralizumab), prompting the need to consider best practice therapeutic decision-making for this indica …
Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD ( …
144 results